Information  X 
Enter a valid email address

BioPharma Credit PLC (BPCR)

  Print   

Friday 08 October, 2021

BioPharma Credit PLC

Confirmation of Delisting from TISE

RNS Number : 4194O
BioPharma Credit PLC
08 October 2021
 

LEI: 213800AV55PYXAS7SY24

8 October 2021

BIOPHARMA CREDIT PLC

(THE "COMPANY")

 

CONFIRMATION OF DELISTING FROM THE INTERNATIONAL EXCHANGE AUTHORITY

 

Further to its announcement on 30 September 2021, BioPharma Credit plc (the "Company" or "BioPharma Credit") confirms the cancellation of the admission of its ordinary shares ("Ordinary Shares") to listing and trading on the Official List of The International Exchange Authority (the "TISE Delisting"). The TISE Delisting was approved by shareholder vote at the general meeting held on 30 September 2021.

The TISE Delisting is expected to become effective today.

The Ordinary Shares will continue to be admitted to listing on the Official List of the Financial Conduct Authority and to trading on the Premium Segment of the London Stock Exchange plc's Main Market.

 

For Further Information

BioPharma Credit plc

Via Link Company Matters Limited

Company Secretary
+44 (0)1392 477 509

 

J.P. Morgan Cazenove 

William Simmonds / Harry Randall (Corporate Finance)

+44 (0)20 7742 4000

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0)20 7466 5000

[email protected]

 

 

About BioPharma Credit plc:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

Visit the BioPharma Credit website at http://bpcruk.com for more information.

Capitalised terms used but not defined in this announcement will have the same meaning as set out in the circular published by the Company on 10 September 2021 unless the context otherwise requires.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCQDLFBFBLFFBL

a d v e r t i s e m e n t